IL97788A - Pharmaceutical composition comprising a complement inhibitor and an immunosuppressant complete with cyclosporin-a like activity for the inhibition of allograft and concordant xenograft rejection - Google Patents

Pharmaceutical composition comprising a complement inhibitor and an immunosuppressant complete with cyclosporin-a like activity for the inhibition of allograft and concordant xenograft rejection

Info

Publication number: IL97788A
Authority: IL; Israel
Prior art keywords: cyclosporin; immunosuppressant; activity; rejection; pharmaceutical composition
Prior art date: 1990-04-09

Application number

IL97788A

Other languages

English (en)

Other versions

IL97788A0 (en

Original Assignee

Imutran Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-09

Filing date

1991-04-08

Publication date

1998-02-08

1991-04-08 Application filed by Imutran Ltd filed Critical Imutran Ltd

1992-06-21 Publication of IL97788A0 publication Critical patent/IL97788A0/xx

1998-02-08 Publication of IL97788A publication Critical patent/IL97788A/en

Links

229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 63
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 63
108010036949 Cyclosporine Proteins 0.000 title claims abstract description 63
229960001265 ciclosporin Drugs 0.000 title claims abstract description 63
230000000694 effects Effects 0.000 title claims abstract description 35
239000004074 complement inhibitor Substances 0.000 title claims abstract description 30
229940124073 Complement inhibitor Drugs 0.000 title claims abstract description 26
229960003444 immunosuppressant agent Drugs 0.000 title claims description 27
230000001861 immunosuppressant effect Effects 0.000 title claims description 27
239000003018 immunosuppressive agent Substances 0.000 title claims description 27
239000008194 pharmaceutical composition Substances 0.000 title claims description 19
230000005764 inhibitory process Effects 0.000 title description 6
230000004083 survival effect Effects 0.000 claims abstract description 45
101710172562 Cobra venom factor Proteins 0.000 claims abstract description 42
229930182912 cyclosporin Natural products 0.000 claims abstract description 24
210000002925 A-like Anatomy 0.000 claims abstract description 18
230000001737 promoting effect Effects 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 7
239000003112 inhibitor Substances 0.000 claims description 5
230000024203 complement activation Effects 0.000 claims description 4
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
230000037361 pathway Effects 0.000 claims description 3
230000015556 catabolic process Effects 0.000 claims description 2
150000002066 eicosanoids Chemical class 0.000 claims description 2
230000007246 mechanism Effects 0.000 claims description 2
150000001875 compounds Chemical class 0.000 abstract description 6
241000894007 species Species 0.000 description 16
238000000034 method Methods 0.000 description 13
238000002360 preparation method Methods 0.000 description 11
241000700159 Rattus Species 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
230000001684 chronic effect Effects 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
241000699800 Cricetinae Species 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
206010052779 Transplant rejections Diseases 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
239000002435 venom Substances 0.000 description 7
210000001048 venom Anatomy 0.000 description 7
231100000611 venom Toxicity 0.000 description 7
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
230000009471 action Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
102000050019 Membrane Cofactor Human genes 0.000 description 4
101710146216 Membrane cofactor protein Proteins 0.000 description 4
241000270295 Serpentes Species 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
239000002642 cobra venom Substances 0.000 description 4
229960004397 cyclophosphamide Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000003998 snake venom Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
108010009575 CD55 Antigens Proteins 0.000 description 3
102000016574 Complement C3-C5 Convertases Human genes 0.000 description 3
108010067641 Complement C3-C5 Convertases Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
239000007927 intramuscular injection Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229940046781 other immunosuppressants in atc Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
102000003712 Complement factor B Human genes 0.000 description 2
108090000056 Complement factor B Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000272041 Naja Species 0.000 description 2
241000272140 Naja kaouthia Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
238000010009 beating Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229960001123 epoprostenol Drugs 0.000 description 2
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000757814 Canis lupus x Canis lupus familiaris Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000272060 Elapidae Species 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
206010048748 Graft loss Diseases 0.000 description 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101710181904 Venom factor Proteins 0.000 description 1
241000271897 Viperidae Species 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
230000003171 anti-complementary effect Effects 0.000 description 1
230000000781 anti-lymphocytic effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
108010019248 cyclosporin C Proteins 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000001492 haemagglutinating effect Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
238000002559 palpation Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012154 short term therapy Methods 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000010911 splenectomy Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Epidemiology (AREA)
Marine Sciences & Fisheries (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Transplantation (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Plant Substances (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL97788A 1990-04-09 1991-04-08 Pharmaceutical composition comprising a complement inhibitor and an immunosuppressant complete with cyclosporin-a like activity for the inhibition of allograft and concordant xenograft rejection IL97788A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909007971A GB9007971D0 (en)	1990-04-09	1990-04-09	Pharmaceutical formulations

Publications (2)

Publication Number	Publication Date
IL97788A0 IL97788A0 (en)	1992-06-21
IL97788A true IL97788A (en)	1998-02-08

Family

ID=10674123

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL97788A IL97788A (en)	1990-04-09	1991-04-08	Pharmaceutical composition comprising a complement inhibitor and an immunosuppressant complete with cyclosporin-a like activity for the inhibition of allograft and concordant xenograft rejection

Country Status (22)

Country	Link
EP (1)	EP0527762B1 (cs)
JP (1)	JP3518547B2 (cs)
CN (1)	CN1040178C (cs)
AT (1)	ATE141167T1 (cs)
AU (1)	AU7555591A (cs)
CZ (1)	CZ283119B6 (cs)
DE (1)	DE69121401T2 (cs)
DK (1)	DK0527762T3 (cs)
ES (1)	ES2090325T3 (cs)
GB (1)	GB9007971D0 (cs)
GR (1)	GR3021642T3 (cs)
HK (1)	HK48597A (cs)
IE (1)	IE911153A1 (cs)
IL (1)	IL97788A (cs)
IN (1)	IN173149B (cs)
MY (1)	MY106158A (cs)
NZ (1)	NZ237739A (cs)
PT (1)	PT97277B (cs)
SG (1)	SG47465A1 (cs)
SK (1)	SK279949B6 (cs)
WO (1)	WO1991015221A1 (cs)
ZA (1)	ZA912467B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60020727T2 (de)	1999-10-27	2006-05-04	Robert London Zhong	Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
AU2001291579B2 (en) *	2000-09-29	2006-08-31	Viron Therapeutics Inc.	Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
EP2338511A3 (en) *	2004-05-14	2012-07-25	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity
US7285530B2 (en)	2004-10-21	2007-10-23	Viron Therapeutics, Inc.	Use of SERP-1 as an antiplatelet agent
EP2073898A1 (en)	2006-10-10	2009-07-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Complement inhibition for improved nerve regeneration
CA2742802C (en)	2008-11-10	2019-11-26	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating complement-associated disorders
SI3011345T1 (sl)	2013-08-07	2017-12-29	Alexion Pharmaceuticals, Inc.	Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)

1990
- 1990-04-09 GB GB909007971A patent/GB9007971D0/en active Pending
1991
- 1991-04-02 MY MYPI91000550A patent/MY106158A/en unknown
- 1991-04-03 ZA ZA912467A patent/ZA912467B/xx unknown
- 1991-04-03 IN IN265MA1991 patent/IN173149B/en unknown
- 1991-04-04 SG SG1996001900A patent/SG47465A1/en unknown
- 1991-04-04 AT AT91907303T patent/ATE141167T1/de not_active IP Right Cessation
- 1991-04-04 DK DK91907303.1T patent/DK0527762T3/da active
- 1991-04-04 AU AU75555/91A patent/AU7555591A/en not_active Abandoned
- 1991-04-04 WO PCT/GB1991/000522 patent/WO1991015221A1/en not_active Ceased
- 1991-04-04 EP EP91907303A patent/EP0527762B1/en not_active Expired - Lifetime
- 1991-04-04 JP JP50651691A patent/JP3518547B2/ja not_active Expired - Fee Related
- 1991-04-04 DE DE69121401T patent/DE69121401T2/de not_active Expired - Fee Related
- 1991-04-04 ES ES91907303T patent/ES2090325T3/es not_active Expired - Lifetime
- 1991-04-08 IL IL97788A patent/IL97788A/en not_active IP Right Cessation
- 1991-04-08 IE IE115391A patent/IE911153A1/en not_active IP Right Cessation
- 1991-04-08 NZ NZ237739A patent/NZ237739A/xx unknown
- 1991-04-08 PT PT97277A patent/PT97277B/pt not_active IP Right Cessation
- 1991-04-09 CZ CS91988A patent/CZ283119B6/cs not_active IP Right Cessation
- 1991-04-09 SK SK988-91A patent/SK279949B6/sk unknown
- 1991-04-09 CN CN91102859A patent/CN1040178C/zh not_active Expired - Fee Related
1996
- 1996-11-14 GR GR960403013T patent/GR3021642T3/el unknown
1997
- 1997-04-17 HK HK48597A patent/HK48597A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1056240A (zh)	1991-11-20
ES2090325T3 (es)	1996-10-16
HK48597A (en)	1997-04-25
PT97277B (pt)	1998-08-31
WO1991015221A1 (en)	1991-10-17
DE69121401D1 (de)	1996-09-19
CS9100988A2 (en)	1991-12-17
DK0527762T3 (da)	1996-09-02
PT97277A (pt)	1992-01-31
AU7555591A (en)	1991-10-30
SK279949B6 (sk)	1999-06-11
DE69121401T2 (de)	1996-12-12
CZ283119B6 (cs)	1998-01-14
NZ237739A (en)	1993-09-27
ZA912467B (en)	1992-12-30
GB9007971D0 (en)	1990-06-06
IL97788A0 (en)	1992-06-21
JPH05507266A (ja)	1993-10-21
MY106158A (en)	1995-03-31
GR3021642T3 (en)	1997-02-28
IE911153A1 (en)	1991-10-09
SG47465A1 (en)	1998-04-17
EP0527762A1 (en)	1993-02-24
IN173149B (cs)	1994-02-19
CN1040178C (zh)	1998-10-14
JP3518547B2 (ja)	2004-04-12
ATE141167T1 (de)	1996-08-15
EP0527762B1 (en)	1996-08-14

Legal Events

Date	Code	Title
1998-07-15	FF	Patent granted
1999-01-26	KB	Patent renewed
2001-07-24	KB	Patent renewed
2005-06-19	KB	Patent renewed
2010-05-17	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
CRAMER et al.	1990	Cardiac transplantation in the rat: II. Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response
KR20040101381A (ko)	2004-12-02	신규한 용도
US8435520B2 (en)	2013-05-07	Combinations of immunosuppressive agents for the treatment or prevention of graft rejections
RU2014837C1 (ru)	1994-06-30	Средство для лечения панкреатита и предупреждения отторжения трансплантата поджелудочной железы и способ предупреждения отторжения трансплантата поджелудочной железы
Hersh	1971	Immunosuppression by L-asparaginase and related enzymes: A review
EP0527762B1 (en)	1996-08-14	Inhibition of allograft and concordant xenograft rejection
US20010018051A1 (en)	2001-08-30	Inhibition of allograft and concordant xenograft rejection
CZ91599A3 (cs)	1999-08-11	Použití bílkovin, extrahovatelných z jater savců
Miyazawa et al.	1995	Hamster to rat kidney xenotransplantation: Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition
Clasen et al.	1988	Long-term treatment of minimal-change nephrotic syndrome with cyclosporin: a control biopsy study
DAVIES et al.	1993	Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival
Anderson et al.	2003	Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation
US8034777B2 (en)	2011-10-11	Modified anticholinergic neurotoxins as modulators of the autoimmune reaction
Hall et al.	1985	Treatment of renal transplantation rejection Cyclosporin A versus conventional treatment with azathioprine, prednisone and antithymocyte immunoglobulin in primary cadaveric renal transplantation
JPS6272621A (ja)	1987-04-03	コレラ毒素類を活性成分とする免疫抑制剤
Kahn et al.	1989	Use of verapamil with conventional immunosuppression after porcine renal transplantation
de Bruin et al.	1990	Small bowel transplantation in rats: the effect of pretransplant donor-specific blood transfusions on various segments of small bowel grafts
DeKlerk et al.	1969	New Methods of Treatment for Renal Allotransplant Using the Baboon as a Primate Experimental Model
de Bruin et al.	1990	The effect of pretransplant donor-specific blood transfusions on various segments of small bowel grafts
US6503948B2 (en)	2003-01-07	Method for prevention or treatment of acute allograft rejection and a pharmaceutical composition therefor
Sobh et al.	1987	Cyclosporine in the treatment of steroid resistant rejection episodes in living donor kidney transplants
Bass	1975	The Eosinophil leucocyte: a cell in search of a role
Murase et al.	1995	Hamster to rat kidney xenotransplantation: effects of FK506, cyclophosphamide, and organ perfusion